Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.55 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15575103 | 0.94 | ALDH1A1 (0.75) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL26144898 | 0.94 | LMNA (0.71) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL925723 | 0.93 | ALDH1A1 (0.78) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL17479215 | 0.93 | ALDH1A1 (0.78) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL26144904 | 0.88 | ALDH1A1 (0.59) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL16222311 | 0.88 | ALDH1A1 (0.64) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL26144953 | 0.88 | ALDH1A1 (0.64) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL26144935 | 0.87 | ALDH1A1 (0.58) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL26144907 | 0.87 | ALDH1A1 (0.58) | LMNAALDH1A1KMT2ACA1CA2 | |
| SCHEMBL2854062 | 0.86 | ALDH1A1 (0.74) | LMNAALDH1A1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-105985265-B | Indenes -1- subunit sulfonyl benzoyl hydrazine derivatives and its preparation method and application | 四川大学 | 2018-11-13 | — | — | CN | disclosed |
| CN-106146361-A | Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use | 四川大学 | 2016-11-23 | — | — | CN | disclosed |
| CN-105985265-A | Indene-1-subunit sulfonyl benzoyl hydrazine derivative as well as preparation method and application thereof | 四川大学 | 2016-10-05 | — | — | CN | disclosed |
| WO-2016001452-A1 | COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED | Universität Zürich (CH) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001452-A1 | COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED | Universität Zürich (CH) | 2016-01-07 | — | — | WO | disclosed |
| WO-2012171488-A1 | COUMARIN DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2012-12-20 | — | — | WO | disclosed |
| CN-102827124-A | Coumarins derivate and medicine composition thereof and application | BEIJING HANMEI PHARMACEUTICAL CO LTD | 2012-12-19 | — | — | CN | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | LMNA 2447/4885ALDH1A1 629/4885KMT2A 2503/4885 |
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | LMNA 3372/4885ALDH1A1 619/4885KMT2A 2857/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | LMNA 2893/4885ALDH1A1 2609/4885KMT2A 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.